Walker on Progress

Benchmark Electronics poaches a key executive from rival Flex, signaling an aggressive push for commercial growth and supply chain resilience under new leadership.

Kim Thinggaard's return as CEO of Enemærke & Petersen signals a strategic doubling-down on the trust-based partnership model he pioneered.

India's new Labour Code 2025 is forcing a strategic pivot. Discover how firms are turning regulatory mandates into a competitive edge for productivity.

Professor Youmin Xi's recent honor signals more than academic success. It marks a strategic blueprint for cultivating the next generation of life science leaders.

A key advisory appointment reveals a pivotal trend in private equity: a move from deal-making to deep operational focus for maximizing portfolio returns.

Trinity Consultants' acquisition of CEQA/NEPA expert Meridian is more than a regional deal; it's a strategic move with deep implications for biopharma.

LRN appoints Bob Lemmond as CEO, a strategic move signaling a deeper push into data-driven ethics amid rising AI regulations and market complexity.

FTI Consulting's new CHRO isn't just a leadership change. It's a strategic move to double down on the one asset that fuels its growth: its people.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

With a new SVP of Growth, John Henry, RestorixHealth signals an aggressive push in the booming wound care market, navigating tech shifts and regulatory hurdles.

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.

A leadership shift at a regional financial powerhouse offers a compelling case study on strategy, innovation, and stakeholder management for biopharma leaders.

A strategic partnership integrates cutting-edge AI into drug development, promising to slash timelines and costs. Is this the new blueprint for pharma R&D?

Cambridge biotech Atavistik Bio reveals a novel allosteric inhibitor targeting a key MPN mutation, promising disease modification without current side effects.

A new partnership aims to merge AI credit scoring with blockchain to tokenize auto loans, targeting a massive traditional finance market for disruption.

With co-founder Kathy Gersch as CEO, Kotter is poised to guide pharma through its next wave of disruption. What does this mean for industry leaders?

With animal trials failing 90% of the time, a new consortium aims to standardize organoid models, promising faster, cheaper, and more human-relevant drug discovery.

Sutton Group appoints a RE/MAX veteran to lead its Eastern expansion, signaling a major push into tech-driven real estate and wealth management.

A barbecue brand's grant to a fire department offers a powerful case study for any industry on leveraging local networks for strategic philanthropy.